TL-895

Phase 2Small molecule

TTelios Pharma, Inc.

TL-895 is one of 118 small molecule programs targeting Systemic Mastocytosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic MastocytosisActive, not recruiting

MyelofibrosisActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

COVID-19Active, not recruiting

Systemic MastocytosisPhase 2

Active, not recruiting

MyelofibrosisPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

COVID-19Phase 1

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

TL-895

TTelios Pharma, Inc.

Phase 2

1 2

Bnt162b2

BioNTech

Preclinical

29 3

COVID-19 Vaccine

Moderna

Preclinical

27 4

Rayaldee

OOrganon and Co

Preclinical

1 5

SARS-COV-2 VACCINE

Moderna

Preclinical

2 6

Glucocorticoid

AbbVie

Preclinical

1 7

Nadroparin

GSK

Preclinical

1 8

Calcium

Olokizumab

1 10

Exoflo

DDirect Biologics, LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Treatment

NCT05280509

Clinical

Trials by Indication[1]

Treatment2 trials

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Unknown status·KKartos Therapeutics, Inc.·Phase 1/2·NCT04640532·116 enrolled

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Recruiting·TTelios Pharma, Inc.·Phase 1/2·NCT05280509·70 enrolled

COVID-191 trial

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

Completed·TTelios Pharma, Inc.·Phase 1·NCT04419623·7 enrolled

Combination Therapy1 trial

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Unknown status·TTelios Pharma, Inc.·Phase 1/2·NCT02825836·130 enrolled

Myelofibrosis1 trial

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Unknown status·KKartos Therapeutics, Inc.·Phase 2·NCT04878003·52 enrolled

Acute Myeloid Leukemia1 trial

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

Unknown status·TTelios Pharma, Inc.·Phase 1/2·NCT04669067·18 enrolled

1 more indication

Systemic Mastocytosis1 trial

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

Recruiting·TTelios Pharma, Inc.·Phase 2·NCT04655118·121 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for TL-895. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TL-895 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TL-895. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Telios Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTelios Pharma, Inc.

TL-895

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Treatment2 trials

COVID-191 trial

Combination Therapy1 trial

Myelofibrosis1 trial

Acute Myeloid Leukemia1 trial

Systemic Mastocytosis1 trial

References

Drug Info

Quick Facts

Related News